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We report a case of intolerance to warfarin dosing due to
impaired drug metabolism in a patient heterozygous for the
CYP2C9*3 allele. A 30-year-old woman with an artificial car-
diac pacemaker was taking warfarin to prevent thromboem-
bolism. This patient had an extremely elevated international
normalized ratio (INR) of prothrombin time (PT) following
standard doses of warfarin and experienced difficulties during
the induction of anticoagulation. Genotyping for CYP2C9
revealed that this patient was an intermediate metabolizer with
genotype CYP2C9*1/*3. This case suggests the clinical use-
fulness of pharmacogenetic testing for individualized dosage
adjustments of warfarin.
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INTRODUCTION
Warfarin, a widely used anticoagulant, may
increase the risk of bleeding complications with
narrow therapeutic index.
1-3 The prolongation of
the prothrombin time (PT) remains the primary
way to measure the anticoagulant effect of war-
farin. Because warfarin is subject to great varia-
bility between individuals in its pharmacokinetics
with effective daily doses ranging from 0.5 mg to
60 mg,
4 therapy should be individualized by moni-
toring patient's international normalized ratio
(INR) of PT.
Warfarin metabolism is catalyzed by CYP2C9,
which metabolizes S-wafarin to inactive S-7-
hydroxywarfarin.
5 A genetic polymorphism of
CYP2C9 contributes to variability among patients
for required maintenance doses of warfarin. Mul-
tiple studies have clearly demonstrated an in-
creased frequency of CYP2C9 allelic variants such
as CYP2C9*2 and CYP2C9*3 in patients stabilized
on low-dose warfarin therapy and have estab-
lished relations between genetic deficiency in
CYP2C9 enzyme activity with increased likelihood
of extremely elevated INRs and major bleeding
events, compared with the general population.
6-11
In this report, we present a case of warfarin
therapy in a patient with the variant CYP2C9
*1/*3, which resulted in decreased activity of
CYP2C9. Extremely prolonged PT during the
induction phase of standard warfarin therapy was
found and a reduction of warfarin dosage was
required to get the target INR in this case.
CASE REPORT
A 30-year-old woman with an artificial cardiac
pacemaker presented to the clinic complaining of
dizziness and dyspnea. The patient had a history
of hypertrophic cardiomyopathy with complete
atrioventricular block and the pacemaker had
been implanted in her 13 years before presenta-
tion. Her prescription medication for the previous
2 years included lasix 20 mg, spironolactone 12.5
mg, imidapril 2.5 mg, and teprenone 50 mg twice
a day.
She had suffered from dizziness and dyspnea
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for the last 2 months and visited the outpatient
clinic. Physical examination of this woman
showed a blood pressure of 110/68 mmHg, a
heart rate of 76 beats/min, and normal body tem-
perature. Her body weight was 45.2 kg and she
was 156 cm in height. Initial laboratory results
were unremarkable with a normal PT of 13.5 sec
(INR 1.03). Cardiomegaly was found on chest
X-ray. Echocardiogram indicated atrial fibrillation.
Echocardiogram also revealed decreased systolic
function and hypertrophy of the left ventricle. The
patient was started on 4 mg of warfarin daily to
prevent thromboembolism.
When she revisited the outpatient clinic after 1
week, her PT was found to be 88.2 sec (INR 6.36)
(Fig. 1). On admission to the ward, 10 mg of
Vitamin K was injected with warfarin withdrawal.
After normalization of the patient's PT, 2 mg/day
of warfarin was initially prescribed and the dose
was then increased to 3 mg/day, which resulted
in a PT of 36.3 - 47.0 sec (INR 2.69 - 3.45). Admini-
stration of warfarin doses was reduced even
further (1 - 2 mg/day) to achieve the target thera-
peutic INR of 2.0 to 3.0 and she was discharged
after 16 days of hospitalization. She continues to
receive warfarin therapy at the outpatient clinic
monthly and her PT remains stable, even though
her warfarin dose has been reduced to 2 mg/day.
This patient was genotyped for CYP2C9. DNA
was isolated from peripheral blood and all 9
exons of CYP2C9 gene were amplified by PCR.
11-13
The PCR products were sequenced using ABI
PRISIM BigDye terminator Cycle sequencing kit
(Perkin-Elmer, USA) and an ABI Prism 3100 Ge-
netic Analyzer (Perkin-Elmer, USA). The patient
was an intermediate metabolizer with the geno-
type of CYP2C9*1/*3 (Fig. 2).
DISCUSSION
CYP2C9, one of the major isoforms of the
CYP2C subfamily, is involved in the metabolism
of many clinically important therapeutic agents
such as warfarin, phenytoin, sulfonylurea and
nonsteroidal anti-inflammatory drugs.
1,11 Genetic
polymorphisms of CYP2C9 bring about significant
variability among individuals in drug response.
At the time of this report,
12 variant alleles of
CYP2C9 had been reported.
14 Previous studies
have demonstrated that 2 common variants
CYP2C9*2 and CYP2C9*3 are associated with
reduced catalytic activity of CYP2C9.
1-11 Therefore,
subjects who are homo- or heterozygous for these
variant alleles require reduced maintenance doses
for CYP2C9 substrates including warfarin. The
CYP2C9*3 variant would have a greater impact
than the CYP2C9*2 variant on the dose require-
ments of warfarin.
2,3,11 Intermediate metabolizers
with heterozygous CYP2C9*2 and CYP2C9*3
would require on average 21% and 34% lower
maintenance doses of warfarin, as compared with
extensive metabolizers (CYP2C9*1/*1).
2 Poor
metabolizers with 2 variant alleles (CYP2C9*2/*2,
CYP2C9*2/*3 and CYP2C9*3/*3) would require 60
- 90% lower doses of warfarin than extensive
metabolizers.
2,3,11
Allele frequencies of CYP2C9 variants have
been shown to be markedly different among
populations. Caucasians possess higher frequen-
cies of CYP2C9*3 than Asians (6-10% vs 2-5%).
1-3
There have been no documented Asian carriers
of the CYP2C9*2 variant, while 8-20% of Cauca-
sians appear to have the CYP2C9*2 allele.
1-11
Fig. 1. Time course of warfarin therapy and international
normalization ratio of prothrombin time.
Fig. 2. Detection of nucleotide changes by sequencing an-
alysis of CYP2C9 gene in the individual heterozygous for
the CYP2C9*3 allele with A1075C (Ile359Leu) substitution.
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Yoon et al reported that from a pool of 574
Koreans 2.3% were heterozygous for CYP2C9*3
and none were found to be carriers of CYP2
C9*2.
15 Interethnic difference in the prevalence of
CYP2C9 variants causes an apparent need for an
interethnic difference in the maintenance dose of
warfarin.
9
There are several Korean reports
16-18 regarding
warfarin dosing and its toxicity based on clinical
assessment and PT monitoring. This case study
is the first clinical report of a Korean patient
with the CYP2C9*1/*3 genotype as the major
determinant of warfarin intolerance. She attained
an extremely high INR at the standard doses
and might be at a higher risk for developing
severe complications. In this patient, we could
not identify any specific pharmacokinetic or
pharmacodynamic factors associated with war-
farin response, such as drug interactions or
disease conditions. Therefore, a pharmacogenetic
test was performed to explore the possible
genetic factors contributing to the unusual drug
response. This patient could have taken appro-
priate therapeutic changes earlier and been
maintained on a safer regimen with lower doses,
if she had been genotyped at the beginning of
warfarin therapy.
The CYP2C9 genotype is associated with a risk
of over-anticoagulation and bleeding complica-
tions. Previous studies have suggested that the
variant group, compared with patients with the
wild-type genotype, required a higher rate of
above-range INR, more time to therapeutic INR,
larger maintenance doses, more time to stable
warfarin dosing, longer hospitalization, and a
higher risk of serious bleeding events.
1-4,6,7,11
At present, clinicians are used to adjusting the
warfarin dose based on PT and clinical response.
Additional CYP2C9 genotyping can serve as an
important guide for more rapid dosage adjust-
ment and prediction of drug response in each
individual. CYP2C9 genotyping is recommended
to complement PT monitoring especially when
the unusual metabolic capacity of warfarin is
suspected. Characterization of CYP2C9 polymor-
phic alleles may identify patients at risk, so that
warfarin can be given more cautiously, espe-
cially during the induction phase of anticoagu-
lation.
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